Baidu
map

iabetologia:2型糖尿病诊断年龄与血糖控制呈负相关

2013-09-06 佚名 丁香园

为了验证年龄小于65岁时诊断2型糖尿病是否与随后的血糖控制欠佳有关,来自美国麻省总医院Seth A Berkowitz教授及其团队进行了一项研究,该研究发现2型糖尿病诊断年龄较小与随后血糖控制欠佳显著相关。

为了验证年龄小于65岁时诊断2型糖尿病是否与随后的血糖控制欠佳有关,来自美国麻省总医院Seth A Berkowitz教授及其团队进行了一项研究,该研究发现2型糖尿病诊断年龄较小与随后血糖控制欠佳显著相关。该研究结果在线发表在2013年9月1日的《Diabetologia》 杂志上。【原文下载】

该研究中,对来自2005–2010年国家健康与营养调查的数据进行横断面分析。自诉糖尿病的成年人,按糖尿病诊断年龄分为年轻组(<65岁)或年长组(≥65岁)。关注的主要结局是HbA1c>9%(75mmol/mol),次要结局是HbA1c>8%(64mmol/mol)和HbA1c>7%(53mmol/mol)。使用多元logistic回归进行分析。

该研究结果表明,在1438例成年糖尿病患者中,糖尿病诊断年龄<65岁与糖尿病诊断年龄≥65岁相比,有更高比例的患者HbA1c>9%.校正性别、种族、受教育程度、收入、保险、平时护理来源、高血糖药物治疗、糖尿病病程、家族史、BMI和腰围后,糖尿病诊断年龄<65岁与HbA1c>9%、HbA1c>8%、HbA1c>7%几率更高显著相关。年轻组报道较少的并发症,但报告的健康状况较差。

该研究发现,2型糖尿病诊断年龄较小与随后血糖控制欠佳显著相关。

原文下载

Berkowitz SA, Meigs JB, Wexler DJ.Age at type 2 diabetes onset and glycaemic control: results from the National Health and Nutrition Examination Survey (NHANES) 2005-2010.Diabetologia. 2013 Sep 1.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1759338, encodeId=f8d51e59338fe, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Nov 04 03:53:00 CST 2013, time=2013-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681936, encodeId=dd36168193695, content=<a href='/topic/show?id=19939159231' target=_blank style='color:#2F92EE;'>#诊断年龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91592, encryptionId=19939159231, topicName=诊断年龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cf527881568, createdName=360611849, createdTime=Fri Jan 10 07:53:00 CST 2014, time=2014-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272895, encodeId=e30112e289528, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Sun Sep 08 02:53:00 CST 2013, time=2013-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573208, encodeId=137415e320826, content=<a href='/topic/show?id=34009226531' target=_blank style='color:#2F92EE;'>#负相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92265, encryptionId=34009226531, topicName=负相关)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2115837741, createdName=hmwwww, createdTime=Sun Sep 08 02:53:00 CST 2013, time=2013-09-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1759338, encodeId=f8d51e59338fe, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Nov 04 03:53:00 CST 2013, time=2013-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681936, encodeId=dd36168193695, content=<a href='/topic/show?id=19939159231' target=_blank style='color:#2F92EE;'>#诊断年龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91592, encryptionId=19939159231, topicName=诊断年龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cf527881568, createdName=360611849, createdTime=Fri Jan 10 07:53:00 CST 2014, time=2014-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272895, encodeId=e30112e289528, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Sun Sep 08 02:53:00 CST 2013, time=2013-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573208, encodeId=137415e320826, content=<a href='/topic/show?id=34009226531' target=_blank style='color:#2F92EE;'>#负相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92265, encryptionId=34009226531, topicName=负相关)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2115837741, createdName=hmwwww, createdTime=Sun Sep 08 02:53:00 CST 2013, time=2013-09-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1759338, encodeId=f8d51e59338fe, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Nov 04 03:53:00 CST 2013, time=2013-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681936, encodeId=dd36168193695, content=<a href='/topic/show?id=19939159231' target=_blank style='color:#2F92EE;'>#诊断年龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91592, encryptionId=19939159231, topicName=诊断年龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cf527881568, createdName=360611849, createdTime=Fri Jan 10 07:53:00 CST 2014, time=2014-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272895, encodeId=e30112e289528, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Sun Sep 08 02:53:00 CST 2013, time=2013-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573208, encodeId=137415e320826, content=<a href='/topic/show?id=34009226531' target=_blank style='color:#2F92EE;'>#负相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92265, encryptionId=34009226531, topicName=负相关)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2115837741, createdName=hmwwww, createdTime=Sun Sep 08 02:53:00 CST 2013, time=2013-09-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1759338, encodeId=f8d51e59338fe, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Nov 04 03:53:00 CST 2013, time=2013-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681936, encodeId=dd36168193695, content=<a href='/topic/show?id=19939159231' target=_blank style='color:#2F92EE;'>#诊断年龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91592, encryptionId=19939159231, topicName=诊断年龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cf527881568, createdName=360611849, createdTime=Fri Jan 10 07:53:00 CST 2014, time=2014-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272895, encodeId=e30112e289528, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Sun Sep 08 02:53:00 CST 2013, time=2013-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573208, encodeId=137415e320826, content=<a href='/topic/show?id=34009226531' target=_blank style='color:#2F92EE;'>#负相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92265, encryptionId=34009226531, topicName=负相关)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2115837741, createdName=hmwwww, createdTime=Sun Sep 08 02:53:00 CST 2013, time=2013-09-08, status=1, ipAttribution=)]
    2013-09-08 hmwwww

相关资讯

Gastroenterology:OCA(法尼酯衍生物X受体拮抗剂)用于治疗2型糖尿病及非酒精性脂肪肝患者的有效性及安全性

6-乙基鹅去氧胆酸(OCA,INT-747)是人初级胆汁酸中鹅去氧胆酸的一种新型衍生物,为法尼酯衍生物X受体(FXR)的天然拮抗剂,是调节葡萄糖和脂质代谢的一种核激素受体。在动物模型中,OCA降低了胰岛素抵抗和肝脏脂肪变性。近日,来自美国加利福利亚大学的Sunder Mudaliar等进行了一项双盲、安慰剂对照研究,评价OCA在2型糖尿病及非酒精性脂肪肝患者中对于胰岛素敏感性作用

2017年中国2型糖尿病药物市场规模将突破35亿美元

最新预测显示,中国已成为继美国和日本后的第三大糖尿病药物市场,并将在2017年前以年均10%的速度增长,届时中国市场的规模将达35亿美元。根据Decision Resources的消息,日益增加的药物治疗患者,以及二肽基肽酶-4抑制剂、胰高血糖素样肽-1受体激动剂和胰岛素类似物日益广泛的使用是糖尿病药物市场规模扩展的主要推手。尽管如预期一样,仿制药会进一步蚕食丧失专利的糖尿病药物市场,但最近上市的

Nature:中外科学家绘制人类肠道菌群图谱

“定居”在人类身体上的细菌数量大约是人类自身细胞的 10 倍,如果要以一个尺度来衡量它们,它的重量大约达到了 1.5kg。由于从前很难或是不太可能在实验室中培养它们,大部分的这些“看不见的乘客”都不为人所知。但在过去的5年里,由法国农业科学研究院(INRA)领导的一直国际联合研究小组利用先进的DNA分析和生物信息方法绘制出了人类肠道菌群的图谱。研究结果发表在《自然》(Natur

JAMA Psychiatry :抗精神病药物的使用增加儿童及青少年2型糖尿病发病风险

抗精神病药物在成年人群中的使用与2型糖尿病风险增加显著相关。而其在儿童和青少年当中使用量的上升,也可能会增加这部分人群2型糖尿病的发病风险。为此,纳什维尔范德比尔特大学医学院的 William V. Bobo博士及其同事进行了一项研究,发现儿童和青少年服用抗精神病药物后出现2型糖尿病的风险增加3倍。该研究结果在线发表于《美国医学会杂志--精神病学》(JAMA期刊网络出版物)上。该研究是对田纳西州医

CSE2013 邹大进:手术治疗肥胖伴2型糖尿病的前景与风险

邹大进正在演讲 近年来,“外科手术治疗2型糖尿病”在全世界医学界领域引起了巨大的关注,人们发现在接手外科手术治疗的肥胖合并2型糖尿病的患者中,术后不仅体重显著下降,而且术后患者的血糖得到改善。一项包含147个相关研究的荟萃分析表明:减肥手术对于体重指数BMI ≥ 40的患者效果最佳,糖尿病缓解率可达64%-100%。另一项包含136个相关研究的荟萃分析也显示:77%的糖尿病患者得到缓

Diabetologia:胃旁路术与胃减容术对血糖和体重的影响相似

减肥手术作为2型糖尿病患者的“代谢性手术干预”方式获得了一定认可,但其最佳手术方式和手术机制仍备受争议。为比较两种减肥手术对伴有2型糖尿病的肥胖症患者的作用,并评估它们对HbA1c和葡萄糖耐量的影响,来自以色列拉宾医学中心的Andrei Keidar教授等人进行了一项研究,发现在HbA1c水平和体重减轻方面,胃旁路术(RYGB)与胃减容术(SG)相比没有更优的疗效。该研究结果在线发表于2013年6

Baidu
map
Baidu
map
Baidu
map